JP2023523706A5 - - Google Patents

Info

Publication number
JP2023523706A5
JP2023523706A5 JP2022563366A JP2022563366A JP2023523706A5 JP 2023523706 A5 JP2023523706 A5 JP 2023523706A5 JP 2022563366 A JP2022563366 A JP 2022563366A JP 2022563366 A JP2022563366 A JP 2022563366A JP 2023523706 A5 JP2023523706 A5 JP 2023523706A5
Authority
JP
Japan
Prior art keywords
kinase inhibitor
pharmaceutical product
rhogenetic
alzheimer
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022563366A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023523706A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/012588 external-priority patent/WO2021216139A1/en
Publication of JP2023523706A publication Critical patent/JP2023523706A/ja
Publication of JP2023523706A5 publication Critical patent/JP2023523706A5/ja
Priority to JP2025282162A priority Critical patent/JP2026053635A/ja
Pending legal-status Critical Current

Links

JP2022563366A 2020-04-23 2021-01-08 アルツハイマー病を治療するためのrhoキナーゼ阻害剤の使用方法 Pending JP2023523706A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025282162A JP2026053635A (ja) 2020-04-23 2025-12-25 アルツハイマー病を治療するためのrhoキナーゼ阻害剤の使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063014272P 2020-04-23 2020-04-23
US63/014,272 2020-04-23
PCT/US2021/012588 WO2021216139A1 (en) 2020-04-23 2021-01-08 Methods of using rho kinase inhibitors to treat alzheimer's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025282162A Division JP2026053635A (ja) 2020-04-23 2025-12-25 アルツハイマー病を治療するためのrhoキナーゼ阻害剤の使用方法

Publications (2)

Publication Number Publication Date
JP2023523706A JP2023523706A (ja) 2023-06-07
JP2023523706A5 true JP2023523706A5 (cg-RX-API-DMAC7.html) 2024-01-11

Family

ID=78269840

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022563366A Pending JP2023523706A (ja) 2020-04-23 2021-01-08 アルツハイマー病を治療するためのrhoキナーゼ阻害剤の使用方法
JP2025282162A Pending JP2026053635A (ja) 2020-04-23 2025-12-25 アルツハイマー病を治療するためのrhoキナーゼ阻害剤の使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025282162A Pending JP2026053635A (ja) 2020-04-23 2025-12-25 アルツハイマー病を治療するためのrhoキナーゼ阻害剤の使用方法

Country Status (7)

Country Link
US (3) US12329761B2 (cg-RX-API-DMAC7.html)
EP (1) EP4138842A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023523706A (cg-RX-API-DMAC7.html)
CN (1) CN115996728A (cg-RX-API-DMAC7.html)
CA (1) CA3175183A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022012957A (cg-RX-API-DMAC7.html)
WO (1) WO2021216139A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11642352B2 (en) * 2020-03-25 2023-05-09 Woolsey Pharmaceuticals, Inc. Methods of treating wandering in Lewy dody dementia
US12329761B2 (en) * 2020-04-23 2025-06-17 Woolsey Pharmaceuticals, Inc. Methods of using rho kinase inhibitors to treat alzheimer's disease
WO2023097151A1 (en) 2021-11-29 2023-06-01 Woolsey Pharmaceuticals, Inc. Methods of treating agitation and other dementia-associated behavioral symptoms
CN115998736B (zh) * 2023-03-28 2023-06-23 中国人民解放军军事科学院军事医学研究院 Y-27632在特异性抑制幻觉作用中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117896A1 (de) 2004-06-03 2005-12-15 Schering Aktiengesellschaft Formulierungen, die fasudil, eine matrix und einem mantel enthalten
US20060212090A1 (en) * 2005-03-01 2006-09-21 Functional Neuroscience Inc. Method of treating cognitive disorders using neuromodulation
EP2061314A4 (en) * 2006-08-10 2010-08-04 Translational Genomics Res Inst CONNECTIONS TO IMPROVE LEARNING AND MEMORY
US20110237600A1 (en) * 2008-05-12 2011-09-29 Amnestix, Inc. Compounds for improving learning and memory
US20120010196A1 (en) * 2010-04-02 2012-01-12 Qin Quingyu Methods of treating neurodegenerative disorders and diseases
EP2825175B1 (en) * 2012-03-12 2017-07-26 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Rho kinase inhibitors for use in treating amyotrophic lateral sclerosis
WO2017003466A1 (en) * 2015-06-30 2017-01-05 University Of South Florida Conversion of non-neuronal cells into neurons
WO2021142183A1 (en) * 2020-01-09 2021-07-15 Woolsey Pharmaceuticals, Inc Methods of treating cortical dementia associated wandering
US11642352B2 (en) 2020-03-25 2023-05-09 Woolsey Pharmaceuticals, Inc. Methods of treating wandering in Lewy dody dementia
US12329761B2 (en) * 2020-04-23 2025-06-17 Woolsey Pharmaceuticals, Inc. Methods of using rho kinase inhibitors to treat alzheimer's disease
US11311553B1 (en) 2020-10-22 2022-04-26 Woolsey Pharmaceuticals, Inc. Methods of treating 4-repeat tauopathies
WO2023097151A1 (en) * 2021-11-29 2023-06-01 Woolsey Pharmaceuticals, Inc. Methods of treating agitation and other dementia-associated behavioral symptoms

Similar Documents

Publication Publication Date Title
CN100528151C (zh) 莫达非尼药物剂型
US4507323A (en) Treatment of psychosexual dysfunctions
JP2025159230A (ja) 睡眠時無呼吸を治療するための方法および組成物
JPH02240021A (ja) 抑うつ障害の治療用に適した制御放出製薬組成物
ES2359441T3 (es) Uso del enantiómero (1s,2r) del milnaciprán para la preparación de un medicamento.
JP2006506378A5 (cg-RX-API-DMAC7.html)
JP2023530120A5 (cg-RX-API-DMAC7.html)
JPH0667841B2 (ja) 恐慌障害の軽減剤
US6075028A (en) Method of treating Tourette's syndrome and related CNS disorders
MX2024010637A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
JP2024507810A5 (cg-RX-API-DMAC7.html)
MX2022012957A (es) Metodos de uso de inhibidores de la quinasa rho para tratar la enfermedad de alzheimer.
Frohlich et al. Clinical trial of guanethidine, a new type of antihypertensive agent
JPH0667842B2 (ja) 基本的うつ病を軽減するためのうつ病治療剤
Aminoff Basic & clinical pharmacology
JP2025517509A5 (cg-RX-API-DMAC7.html)
US20050256131A1 (en) Pharmaceutical active substance combination and the use thereof
JP2021512086A5 (cg-RX-API-DMAC7.html)
US4260600A (en) Method of treating depression
JP2023516753A5 (cg-RX-API-DMAC7.html)
IE58734B1 (en) Use of propiophenone compounds
WO2004017973A1 (ja) 統合失調症治療剤
AU2002363874A1 (en) Use of desoxypeganine for treating clinical depression
CN109562180B (zh) 组胺-3受体反向激动剂、乙酰胆碱酯酶抑制剂和nmda受体拮抗剂的三重组合产品
Kiersch et al. The onset of action and the analgesic efficacy of Saridon®*(a propyphenazone/paracetamol/caffeine combination) in comparison with paracetamol, ibuprofen, aspirin and placebo (pooled statistical analysis)